271 related articles for article (PubMed ID: 31300404)
1. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.
Freeman CL; Kridel R; Moccia AA; Savage KJ; Villa DR; Scott DW; Gerrie AS; Ferguson D; Cafferty F; Slack GW; Farinha P; Skinnider B; Connors JM; Sehn LH
Blood; 2019 Aug; 134(9):761-764. PubMed ID: 31300404
[TBL] [Abstract][Full Text] [Related]
2. Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C; Lok A; Tessoulin B; Gastinne T; Mahé B; Dubruille V; Blin N; Touzeau C; Moreau A; Bossard C; Peterlin P; Garnier A; Guillaume T; Le Bourgeois A; Chevallier P; Moreau P; Leux C; Le Gouill S
Ann Hematol; 2020 Jul; 99(7):1595-1604. PubMed ID: 32417940
[TBL] [Abstract][Full Text] [Related]
3. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
[TBL] [Abstract][Full Text] [Related]
4. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Watanabe T; Matsuno Y; Wakabayashi M; Maruyama D; Yamamoto K; Kubota N; Shimada K; Asagoe K; Yamaguchi M; Ando K; Ogura M; Kuroda J; Suehiro Y; Tsukasaki K; Tobinai K; Nagai H
Hematol Oncol; 2024 May; 42(3):e3272. PubMed ID: 38595316
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.
Cheah CY; Chihara D; Ahmed M; Davis RE; Nastoupil LJ; Phansalkar K; Hagemeister FB; Fayad LE; Westin JR; Oki Y; Fanale MA; Romaguera JE; Wang ML; Lee H; Turturro F; Samaniego F; Rodriguez MA; Neelapu SS; Fowler NH
Ann Oncol; 2016 May; 27(5):895-901. PubMed ID: 26802151
[TBL] [Abstract][Full Text] [Related]
8. Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months.
Yoon SE; Cho J; Kim WS; Kim SJ
J Cancer; 2021; 12(9):2488-2497. PubMed ID: 33854610
[No Abstract] [Full Text] [Related]
9. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
[TBL] [Abstract][Full Text] [Related]
11. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
Tobin JWD; Keane C; Gunawardana J; Mollee P; Birch S; Hoang T; Lee J; Li L; Huang L; Murigneux V; Fink JL; Matigian N; Vari F; Francis S; Kridel R; Weigert O; Haebe S; Jurinovic V; Klapper W; Steidl C; Sehn LH; Law SC; Wykes MN; Gandhi MK
J Clin Oncol; 2019 Dec; 37(34):3300-3309. PubMed ID: 31461379
[TBL] [Abstract][Full Text] [Related]
12. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
Trotman J; Cheah CY; Marlton P; Opat S
Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
14. Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report.
Cerchione C; Nappi D; Musuraca G; Lucchesi A; Cimmino I; Pane F; De Renzo A; Martinelli G
Medicine (Baltimore); 2020 Aug; 99(33):e21440. PubMed ID: 32871991
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
Rai S; Inoue H; Sakai K; Hanamoto H; Matsuda M; Maeda Y; Haeno T; Watatani Y; Kumode T; Serizawa K; Taniguchi Y; Hirase C; Espinoza JL; Morita Y; Tanaka H; Ashida T; Tatsumi Y; Nishio K; Matsumura I
Cancer Sci; 2022 Feb; 113(2):660-673. PubMed ID: 34837284
[TBL] [Abstract][Full Text] [Related]
16. Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.
Jacobson CA; Freedman AS
Curr Hematol Malig Rep; 2016 Jun; 11(3):218-23. PubMed ID: 26995595
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
[TBL] [Abstract][Full Text] [Related]
18. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
19. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
